Journal: Oncology reports

Article Title: AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.

doi: 10.3892/or.2017.5482

Figure Lengend Snippet: Figure 2. Inhibition of AXL and MET activity reduces migration and invasion of NSCLC cells. (A and B) Cells were treated with PHA665752 or XL880, and drug sensitivity was determined by MTT assay. (C) Cells were treated with the indicated doses of PHA665752 and XL880 for 24 h. Inhibition of AXL and MET activity were determined by western blotting. (D and E) Cells were treated with 1 µM PHA665752 or 1 µM XL880 and experiments were performed as in Fig. 1C and D. *P<0.1, **P<0.01, and #P<0.001 in comparison with control cells.

Article Snippet: PHA665752 and XL880 were purchased from Selleck Chemicals (Houston, TX, uSA).

Techniques: Inhibition, Activity Assay, Migration, MTT Assay, Western Blot, Comparison, Control

Journal: Clinical Cancer Research

Article Title: Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR–MET Interaction and Activation of MET Signaling in Colon Cancer Cells

doi: 10.1158/1078-0432.ccr-13-0423

Figure Lengend Snippet: Figure 4. PHA655752 restores sensitivity of GEO-CR and SW48- CR cells to cetuximab. A and C, GEO, GEO-CR (A), SW48, and SW48-CR (C) cells were treated with increased concentrations of PHA665752 (0.01–10 nmol/L) for 96 hours and evaluated for cell proliferation by MTT staining, as described in Materials and Methods. The results are the average SD of three independent experiments, each done in quadruplicate. B and D, GEO-CR (B) and SW48-CR (D) cells were treated with 2 doses of PHA665752 (0.01 or 0.05 nmol/L for GEO-CR and 5 or 10 nmol/L for SW48-CR), with increasing concentrations of cetuximab (0.01–10 mg/mL) or with a combination of both drugs for 96 hours and evaluated for cell proliferation by MTT staining, as described in Materials and Methods. The results are the average SD of three independent experiments, each done in quadruplicate. E and F, GEO-CR (E) and SW48-CR (F) cells were treated with PHA665752, cetuximab, or their combination at the indicated concentrations for 24 hours. The cell lysates were assayed by Western blotting with the indicated antibodies, as described in Materials and Methods. G and H, GEO-CR (G) and SW48-CR (H) cells were treated with PHA665752, cetuximab, or their combination at the indicated concentrations and analysis of in vitro cell migration was performed as described in Materials and Methods.

Article Snippet: PHA665752, a selective MET tyrosine kinase inhibitor (TKI), was purchased from Santa Cruz Biotechnology.

Techniques: Staining, Western Blot, In Vitro, Migration

Journal: Genes & Cancer

Article Title: Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer

doi: 10.18632/genesandcancer.148

Figure Lengend Snippet: List of c-Met inhibitors

Article Snippet: c-Met inhibitors (AMG-208, BMS 777607, Cabozantinib, Crizotinib, Foretinib, NVP-BVU972, PF-04217903, PHA-665752, Tivantinib) were purchased from Namiki Inc. (Japan).

Techniques: